hydroxychloroquine has been researched along with Communicable Diseases in 4 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Communicable Diseases: An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Chloroquine and hydroxychloroquine, with an original indication to prevent or cure malaria, have been successfully used to treat several infectious (HIV, Q fever, Whipple's disease, fungal infections), rheumatological (systemic lupus erythematosus, antiphospholipid antibody syndrome, rheumatoid arthritis, Sjögren's syndrome), and other immunological diseases." | 4.98 | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. ( Koudriavtseva, T; Plantone, D, 2018) |
| " Additional liabilities of these medications include pharmacokinetic profiles that require extended dosing to achieve therapeutic tissue concentrations." | 2.66 | Nanomedicine Reformulation of Chloroquine and Hydroxychloroquine. ( Crist, RM; Stern, ST; Stevens, DM, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hernandez-Cardenas, C | 1 |
| Thirion-Romero, I | 1 |
| Rodríguez-Llamazares, S | 1 |
| Rivera-Martinez, NE | 1 |
| Meza-Meneses, P | 1 |
| Remigio-Luna, A | 1 |
| Perez-Padilla, R | 1 |
| Barbosa, AN | 1 |
| Chebabo, A | 1 |
| Starling, C | 1 |
| Pérez, C | 1 |
| Cunha, CA | 1 |
| de Luna, D | 1 |
| Nunes, EP | 1 |
| Zambrano, G | 1 |
| Ferreira, JC | 1 |
| Croda, J | 1 |
| Falavigna, M | 1 |
| Gomes-da-Silva, MM | 1 |
| Thormann, M | 1 |
| Cimerman, S | 1 |
| Parahiba, SM | 1 |
| Tanni, S | 1 |
| Bernardo, WM | 1 |
| Rodriguez-Morales, AJ | 1 |
| Stevens, DM | 1 |
| Crist, RM | 1 |
| Stern, ST | 1 |
| Plantone, D | 1 |
| Koudriavtseva, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study[NCT04326725] | 80 participants (Anticipated) | Observational | 2020-03-20 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for hydroxychloroquine and Communicable Diseases
| Article | Year |
|---|---|
Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API).
Topics: Antiviral Agents; Brazil; Communicable Diseases; COVID-19; Humans; Hydroxychloroquine; Ivermectin; P | 2023 |
Nanomedicine Reformulation of Chloroquine and Hydroxychloroquine.
Topics: Animals; Antimalarials; Chloroquine; Communicable Diseases; Drug Compounding; Humans; Hydroxychloroq | 2020 |
Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antimalarials; Antineoplastic Agents; Antirheumatic | 2018 |
1 trial available for hydroxychloroquine and Communicable Diseases
| Article | Year |
|---|---|
Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: A randomized controlled trial.
Topics: Adult; Antiviral Agents; Communicable Diseases; COVID-19; COVID-19 Drug Treatment; Double-Blind Meth | 2021 |